---
layout: post
title: "Mucopolysaccharidosis Type III (Sanfilippo Syndrome): Developing Drugs for Treatment; Draft Guidance for Industry; Availability"
date: 2026-02-05 19:08:25 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2020-02220
original_published: 2020-02-05 00:00:00 +0000
significance: 8.00
---

# Mucopolysaccharidosis Type III (Sanfilippo Syndrome): Developing Drugs for Treatment; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 19:08 UTC
**Source:** Federal Register
**Original Published:** February 05, 2020 00:00 UTC
**Document Number:** 2020-02220

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Mucopolysaccharidosis Type III (Sanfilippo Syndrome): Developing Drugs for Treatment." The purpose of this draft guidance is to foster greater efficiency in drug development in this rare disease with the goal of enhancing clinical trial data quality and supporting the development of treatments for mucopolysaccharidosis type III. Specifically, the draft guidance provides the Agency's current recommendations regarding eligibility criteria, trial design considerations, and efficacy endpoints for use in clinical development programs of investigational drugs to treat mucopolysaccharidosis type III.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2020/02/05/2020-02220/mucopolysaccharidosis-type-iii-sanfilippo-syndrome-developing-drugs-for-treatment-draft-guidance-for)
- API: https://www.federalregister.gov/api/v1/documents/2020-02220

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
